Bryant Lim Biography and Net Worth

CFO of Prelude Therapeutics

Bryant D. Lim joined Prelude Therapeutics in 2023 as Chief Legal Officer and Corporate Secretary. In addition, he was appointed Chief Financial Officer (CFO) in February 2025, after serving as interim CFO since April 2024. He has more than 25 years of experience in pharma and biotech leadership, with expertise in business development, regulatory, quality, compliance, fundraising and SEC reporting. Prior to joining Prelude, Mr. Lim was Chief Business Officer and General Counsel at Aceragen, Inc. (previously Idera Pharmaceuticals). Previous to that, he served as Vice President of Legal at Incyte Corporation, having previously served as the Global Chief Compliance Officer. Earlier in his career, he was associate general counsel at ViroPharma Incorporated (until its acquisition by Shire Pharmaceuticals) and assistant counsel at Merck & Co., Inc. He currently serves as Chairman of the Board of Directors of Life Sciences of Pennsylvania. Mr. Lim earned his law degree from Villanova University School of Law.

What is Bryant David Lim's net worth?: The estimated net worth of Bryant David Lim is at least $132.62 thousand as of December 19th, 2024. Mr. Lim owns 27,400 shares of Prelude Therapeutics stock worth more than $132,616 as of May 7th. This net worth evaluation does not reflect any other assets that Mr. Lim may own. Learn More about Bryant David Lim's net worth.
How do I contact Bryant David Lim?: The corporate mailing address for Mr. Lim and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on Bryant David Lim's contact information.
Has Bryant David Lim been buying or selling shares of Prelude Therapeutics?: Bryant David Lim has not been actively trading shares of Prelude Therapeutics during the past quarter. Most recently, on Thursday, December 19th, Bryant David Lim bought 25,000 shares of Prelude Therapeutics stock. The stock was acquired at an average cost of $0.91 per share, with a total value of $22,750.00. Following the completion of the transaction, the chief financial officer now directly owns 27,400 shares of the company's stock, valued at $24,934. Learn More on Bryant David Lim's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes Andrew Combs (EVP), Bryant Lim (CFO), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.
Are insiders buying or selling shares of Prelude Therapeutics?: In the last year, Prelude Therapeutics insiders bought shares 2 times. They purchased a total of 5,630,630 shares worth more than $24,999,997.20. The most recent insider tranaction occured on April, 21st when Director David P Bonita bought 2,815,315 shares worth more than $12,499,998.60. Insiders at Prelude Therapeutics own 63.9% of the company. Learn More about insider trades at Prelude Therapeutics.
Information on this page was last updated on 4/21/2026.

Bryant David Lim Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/19/2024	Buy	25,000	$0.91	$22,750.00	27,400

Bryant David Lim Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $4.87

$4.65

$4.88

50 Day Range

MA: $3.73

$2.63

$5.52

2 Week Range

Now: $4.87

$0.75

$5.54

Volume

28,008 shs

Average Volume

395,355 shs

Market Capitalization

$306.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11